Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Synergistic Antimicrobial Therapy Using Nanoparticles and Antibiotics for the Treatment of Multidrug-Resistant Bacterial Infection Publisher



Gupta A1 ; Saleh NM1, 2 ; Das R1 ; Landis RF1 ; Bigdeli A1 ; Motamedchaboki K3 ; Campos AR3 ; Pomeroy K3 ; Mahmoudi M4, 5 ; Rotello VM1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, 01003, MA, United States
  2. 2. Department of Microbiology, National Organization for Drug Control and Research (NODCAR), Pyramids Ave, Giza, 12553, Egypt
  3. 3. Center Proteomics Facility, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 92037, CA, United States
  4. 4. Nanotechnology Research Center and Department of Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
  5. 5. Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, 02115, MA, United States

Source: Nano Futures Published:2017


Abstract

Infections caused by multidrug-resistant (MDR) bacteria pose a serious global burden of mortality, causing thousands of deaths each year. Antibiotic treatment of resistant infections further contributes to the rapidly increasing number of antibiotic-resistant species and strains. Synthetic macromolecules such as nanoparticles (NPs) exhibit broad-spectrum activity against MDR species, however lack of specificity towards bacteria relative to their mammalian hosts limits their widespread therapeutic application. Here, we demonstrate synergistic antimicrobial therapy using hydrophobically functionalized NPs and fluoroquinolone antibiotics for treatment of MDR bacterial strains. An 8–16-fold decrease in antibiotic dosage is achieved in presence of engineered NPs to combat MDR strains. This strategy demonstrates the potential of using NPs to ‘revive’ antibiotics that have been rendered ineffective due to the development of resistance by pathogenic bacteria. © 2017 IOP Publishing Ltd.